Sindrome.del.Ovario.Poliquistico

Tratamiento en mujeres sin deseo genésico 111
12
Guzick DS, Wing R, Smith D, Berga SL,
Winters SJ. Endocrine consequences
of weight loss in obese, hyperandrogenic,
anovulatory women. Fertil Steril.
1994;61:598-604.
13
Clark AM, Ledger W, Galletly C, Tomlinson
L, Blaney F, Wang X, et al. Weight
loss results in significant improvement
in pregnancy and ovulation rates in
anovulatory obese women. Hum Reprod.
1995;10:2705-12.
14
Pasquali R, Antenucci D, Casimirri F,
Venturoli S, Paradisi R, Fabbri R, et al.
Clinical and hormonal characteristics
of obese amenorrheic hyperandrogenic
women before and after weight loss. J
Clin Endocrinol Metab. 1989;68:173-9.
15
Kiddy DS, Hamilton-Fairley D, Bush
A, Short F, Anyaoku V, Reed MJ, et al.
Improvement in endocrine and ovarian
function during dietary treatment
of obese women with polycystic ovary
syndrome. Clin Endocrinol (Oxf). 1992;
36:105-11.
16
Moran LJ, Noakes M, Clifton PM, et al.
Dietary composition in restoring reproductive
and metabolic physiology in
overweight women with polycystic ovary
syndrome. J Clin Endocrinol Metab.
2003;88:812-9.
17
Holte J, Bergh T, Berne C, Wide L,
Lithell H. Restored insulin sensitivity
but persistently increased early insulin
secretion after weight loss in obese
women with polycystic ovary syndrome.
J Clin Endocrinol Metab. 1995;80:
2586-93.
18
Maggio CA, Pi-Sunyer FX. The prevention
and treatment of obesity. Diabetes
Care. 1997;20:1744-66.
19
Ferriman D, Gallwey JD. Clinical assessment
of body hair growth in women.
J Clin Endocrinol Metabol. 1961;21:
1440-8.
20
Prelevic GM. Hirsutism and the polycystic
ovary syndrome. In: Ginsburg
J, editor. Drug therapy in reproductive
endocrinology. London: Arnold; 1996. p.
67-85.
21
Sahin Y, Kelestimur F. Medical treatment
regimens of hirsutism. Reprod Biomed
Online. 2004;8(5):538-46.
22
Givens JR, Andersen RN, Wiser WL,
Fish SA. Dynamics of suppression and
recovery of plasma FSH, LH, androstenedione
and testosterone in polycystic
ovarian disease using an oral contraceptive.
J Clin Endocrinol Metab. 1974;38:
727-35.
23
Wiebe RH, Morris CV. Effect of an oral
contraceptive on adrenal and ovarian
androgenic steroids. Obstet Gynecol.
1984;63(1):12-4.
24
Aydilink S, Kaufman J, Lachnit O, Fixon
U, Lehnert J. Long-term therapy of signs
of androgenization with a low dosed
antiandogen-oestrogen combination.
Clin Trial J. 1990;27:392-402.
25
Prelevic GM, Puzigaca Z, Balint-Peric
LA. Effects of an oral contraceptive
containing cyproterone acetate (Diane-
35) on the symptoms, hormone profile,
and ovarian volume of hirsute women
with polycystic ovarian syndrome. Ann
N Y Acad Sci. 1993;687:255-62.
26
Reaman HE, De Viries CS, Farmer RC.
Venous thromboembolism associated
with cyproterone acetate in combination
with ethinyloestradiol (Dianette): observational
studies using the UK General
Practice Research Database. Pharmacoepidemiol
Drug Saf. 2004;13:427-36.
27
Palep-Singh M, Mook K, Barth J, Balen A.
An observational study of Yasmin in the
management of women with polycystic
ovary syndrome. J Fam Plann Reprod
Health Care. 2004;30:163-5.
28
Guido M, Romualdi D, Giuliani M,
Suriano R, Selvaggi L, Apa R, et al. Drospirenone
for the treatment of hirsute
women with polycystic ovary syndrome:
a clinical, endocrinological, metabolic
pilot study. J Clin Endocrinol Metab.
2004;89:2817-23.
29
McMullen GR, Van Herle AJ. Hirsutism
and the effectiveness of spironolactone
in its management. J Endocrinol Invest.
1993;16:925-32.